Гисталонг is an international brand name for the active substance astemizole. This compound is categorized as an antihistamine medication.

Quick Facts

• Therapeutic Domain: Treatment of symptoms associated with specific allergic conditions.
• Primary Uses: Management of allergic rhinitis, including seasonal allergic rhinitis (hay fever).
• Additional Use: Relief of symptoms related to chronic urticaria (hives).

What Гисталонг Treats: Main Uses and Benefits

The primary therapeutic role of astemizole is to provide relief from symptoms linked to allergic reactions. It is indicated for the management of allergic rhinitis, which includes symptoms such as sneezing, rhinorrhea (runny nose), and pruritus (itching) of the nose and eyes. It is also indicated for the treatment of chronic urticaria, a condition characterized by recurrent hives or welts on the skin.

A key benefit of this compound is its prolonged duration of action, which allowed for once-daily dosing. Furthermore, it was historically classified as a non-sedating antihistamine, which meant it was less likely to cause central nervous system depression or drowsiness compared to older medications in the same class.

It is important to note that due to potential for serious cardiac adverse events, the regulatory status of astemizole has changed in many countries. It was withdrawn from various markets, including the U.S., in light of these safety considerations.

Eligibility Map: Who can and cannot use Гисталонг — Official Regulatory Information

The regulatory eligibility profile for Astemizole is primarily defined by its market status: the drug was withdrawn from sale for safety reasons in major territories like the U.S. due to the risk of severe cardiac arrhythmias (QT prolongation). This official designation makes the drug non-eligible for general use.

Eligibility Scope	Regulatory Status
Populations for whom use is contraindicated:	Patients with known hypersensitivity, severe hepatic dysfunction, or those concomitantly receiving azole antifungals (e.g., ketoconazole) or macrolide antibiotics (e.g., erythromycin).
Age-related eligibility rules:	Formerly indicated for adults and adolescents. Special caution is required for older adults due to potentially heightened cardiac risk.
Pregnancy and lactation eligibility status:	Assigned Pregnancy Category C; use is restricted only if potential benefit justifies the risk. Use during breastfeeding is advised against as excretion into human milk is unknown.

Eligibility-related restrictions: Patients with renal impairment, pre-existing heart disease, or uncorrected low potassium levels require special monitoring. The official regulatory basis for non-eligibility is the determined safety risk, which constitutes the overriding constraint on who can use the medicine.

Interactions with other medicines and products

Official regulatory information for astemizole defines a strict interaction profile primarily based on metabolic and cardiac risks.

Interaction Scope

Classification	Officially Documented Interactions
Contraindicated Combinations	Co-administration is formally prohibited with potent CYP3A4 inhibitors, including specific macrolide antibiotics (e.g., erythromycin, clarithromycin) and azole antifungals (e.g., ketoconazole, itraconazole), as well as certain HIV protease inhibitors.
Pharmacodynamic Risk	Contraindicated with other medicines that cause QT interval prolongation (e.g., specific antiarrhythmics) due to the additive risk of life-threatening ventricular arrhythmias.
Food/Substance Restriction	Consumption of grapefruit juice is restricted, as it inhibits the metabolism of astemizole, leading to increased systemic exposure. The product should be taken on an empty stomach.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction Severity	Major/Contraindicated. The risk of cardiotoxicity arising from increased plasma concentration is officially classified as a major restriction.
Population-Specific Note	Use is restricted or contraindicated in patients with hepatic dysfunction because impaired liver function elevates the interaction risk.

---

This structure ensures adherence to regulatory constraints by defining strict prohibitions against co-administration with substances that impair metabolic clearance or increase cardiac electrophysiological risk, as detailed in governmental prescribing documents.

How Гисталонг Works

Гисталонг (Astemizole) exerts its pharmacodynamic activity through its core molecule and primary active metabolite (desmethylastemizole) by modulating distinct biological systems and signaling pathways.

1. Selective Histamine H1-Receptor Blockade

The primary mechanism involves acting as a selective antagonist, competitively binding to peripheral Histamine H1 receptors. This interaction prevents the body's natural histamine from binding and activating the receptor, thereby inhibiting the signal transduction cascade initiated by histamine. This targeted effect limits the activation and subsequent downstream effects of excessive mediator activity.

2. Ion Channel Pathway Modulation

A secondary effect influences voltage-gated potassium ion channels, specifically the hERG channel which conducts the IKr current in the heart. The drug and its metabolite bind to and inhibit this channel, directly modulating electrochemical flow. This targeted pathway interference is relevant in the system governing cardiac electrical activity, modulating the regulatory processes driven by distinct signaling patterns in myocardial repolarization.

Гисталонг is administered via the oral route in the form of tablets or oral suspension. The administration schedule is based on the drug's long-acting profile.

Standard Labeled Dosage and Frequency

The standard dose for adults and children aged 12 years and older is 10 mg, taken once daily. This 10 mg dose represents the maximum recommended daily dose and must not be exceeded. The medication is used with a once-daily frequency for the purpose of continuous, sustained management, and is not intended for use as an as-needed (prn) treatment.

Population	Official Daily Dose	Frequency
Adults (ge 12 years)	10 mg	Once daily
Children (6–11 years)	5 mg	Once daily

Administration Specifics

A critical instruction related to proper administration is the requirement that the dose be taken on an empty stomach. This is defined as two hours after a meal, with no additional food consumed for one hour following the dose. Tablets must be swallowed whole with water and should not be crushed or broken. If a dose is missed, it is standard to resume the regular once-daily schedule and not to double the next dose. These instructions define the standardized use of the medication.

Evidence for Use in Allergic Rhinitis

Research has focused on the evaluation of Гисталонг in allergic rhinitis (hay fever) through Systematic Reviews and Randomized Controlled Trials (RCTs) involving adult and adolescent populations. Studies explored short-term symptom changes, primarily measuring physical discomfort outcomes like sneezing, runny nose, and itching. Research describes patterns where the full measured change occurred several days after the treatment was initiated. Studies also report that measurement of nasal blockage or congestion showed limited change.

Evidence for Use in Chronic Urticaria

Research also examined Гисталонг in chronic idiopathic urticaria (long-lasting hives) using double-blind, placebo-controlled trials in adult patients. Studies monitored outcomes related to inflammatory states, measuring changes in the severity and frequency of hives. Researchers tracked specific physical manifestations, including the size of wheals and associated itching (pruritus). Findings report how symptoms evolved in the observed populations during the trial periods.

Long-Term Studies and Follow-up

Trials for clinical evaluation were typically short-term, observing responses for 4 to 12 weeks. While these studies contribute to understanding short-term changes, follow-up durations were limited in the most rigorous trial designs. Some open-label research extended up to one year, describing symptom patterns over extended use, but comprehensive, long-term outcomes regarding durability are not fully established.

Evidence in Specific Populations and Uncertainty

The majority of controlled trials primarily examined adult and adolescent patients, meaning data for certain groups, such as very young children or older adults, remain insufficient. Limitations also exist regarding individuals with multiple concurrent health conditions (comorbidities). Furthermore, the evidence gap suggests that long-term physiological effects are not fully established in the research record, highlighting areas where more research is still needed.

Common questions about Гисталонг (FAQ)

Q: How is Гисталонг different from other common allergy medicines?

According to official product information, Гисталонг is classified as a second-generation antihistamine notable for its long duration of action, which supports continuous relief from symptoms. The drug was generally described as having a low risk of sedation at approved doses. However, regulatory bodies emphasized the potential for serious cardiac side effects, which resulted in its market withdrawal in some major territories.

---

Q: How long does it typically take for Гисталонг to start working?

Studies indicate that patients may begin to experience symptom relief within 4 to 6 hours after taking the medicine. The full effects are commonly observed within 24 hours of administration. Regulatory documents indicate that increasing the dose is not recommended, as the onset of action occurs over a period of hours.

---

Q: What official information is available regarding driving or operating machinery while taking Гисталонг?

Regulatory warnings state that the medicine may cause side effects such as dizziness or drowsiness. If these effects occur, official warnings state that activities requiring full attention, such as driving a motor vehicle or operating machinery, should be avoided.

---

Q: What contraindications are listed in the official documents for Гисталонг?

Official documents list strict contraindications (reasons the medicine should not be used). These involve specific substances that interfere with metabolism, such as certain macrolide antibiotics, azole antifungals, and grapefruit products. Use is also restricted for individuals with pre-existing conditions like heart disease, liver impairment, or specific electrolyte imbalances (e.g., low potassium).

---

Q: Can children use Гисталонг?

Regulatory guidance historically included specific dosing information for children aged 6 to 11 years and adolescents aged 12 years and older. This information defined the populations for which the drug was indicated.

---

Q: Is Гисталонг safe to use during pregnancy, according to official sources?

Official documents classify the drug as Pregnancy Category C. This classification indicates that the medicine should be used only if the potential benefit is considered to justify the potential risk, as controlled studies in human pregnancy are unavailable.

---

Q: What is known about using Гисталонг while breastfeeding?

Official data regarding the medicine's excretion into human milk are unknown. Due to its chemical properties, passage into breast milk is considered probable. For this reason, official regulatory documents generally advise against its use while breastfeeding.

---

Q: Are there any known long-term effects?

Regulatory reports indicate that an increase in appetite and subsequent weight gain were documented effects in approximately 4% of patients during long-term use. This information is based on the safety profile established in clinical studies.

---

Q: Is there a generic version of Гисталонг available?

The US Food and Drug Administration (FDA) determined that the drug was withdrawn from sale for safety reasons. As a result of this regulatory status, the agency stated it would not approve generic applications for the product.

---

Q: Does alcohol consumption present a significant risk while using Гисталонг?

Clinical research has not demonstrated an interaction of the medicine on the elimination of alcohol from the body. However, official warnings generally mention that the use of alcohol warrants caution due to the drug's potential to cause common side effects like dizziness or drowsiness.

---

Q: Does long-term use of Гисталонг require any specific medical monitoring?

The safety profile requires that individuals with pre-existing health conditions, such as heart disease, liver impairment, or electrolyte imbalances, may require special medical monitoring. This monitoring is needed to mitigate the cardiac risk associated with the medicine.

---

Q: Does Гисталонг interact with antibiotics?

Official documents strictly contraindicate the use of Гисталонг with specific types of antibiotics, particularly macrolides (e.g., erythromycin). This restriction is necessary due to the significant and potentially serious risk of adverse cardiac side effects when the medications are combined.

Storage and Disposal Information

Official regulatory documentation mandates specific conditions to ensure the quality and stability of Гисталонг. The medicine must be stored in a dry place and a location protected from light. Crucially, the storage temperature must not exceed 25 °C.

Storage Domain	Official Requirement
Temperature	Not exceeding 25 °C
Environment	Dry place, protected from light

These constraints define the required conditions to maintain the drug's labeled effectiveness until its expiration date. While instructions for its storage are precise, specific disposal requirements for unused or expired quantities are typically covered by general regulatory guidelines on pharmaceutical waste.